Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1998 Nov;65(5):709–716. doi: 10.1136/jnnp.65.5.709

Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up

K Pietz 1, P Hagell 1, P Odin 1
PMCID: PMC2170363  PMID: 9810943

Abstract

OBJECTIVES—Despite the recent introduction of new peroral drugs as well as neurosurgical methods for Parkinson's disease, treatment of late stage parkinsonian patients remains difficult and many patients become severely handicapped because of fluctuations in their motor status. Injections and infusions of apomorphine has been suggested as an alternative in the treatment of these patients, but the number of studies describing the effects of such a treatment over longer time periods is still limited. The objective was to investigate the therapeutic response and range of side effects during long term treatment with apomorphine in advanced Parkinson's disease.
METHODS—Forty nine patients (30 men, 19 women; age range 42-80 years) with Parkinson's disease were treated for 3 to 66 months with intermittent subcutaneous injections or continuous infusions of apomorphine.
RESULTS—Most of the patients experienced a long term symptomatic improvement. The time spent in "off" was significantly reduced from 50 to 29.5% with injections and from 50 to 25% with infusions of apomorphine. The quality of the remaining "off" periods was improved with infusion treatment, but was relatively unaffected by apomorphine injections. The overall frequency and intensity of dyskinesias did not change. The therapeutic effects of apomorphine were stable over time. The most common side effect was local inflammation at the subcutaneous infusion site, whereas the most severe were psychiatric side effects occurring in 44% of the infusion and 12% of the injection treated patients.
CONCLUSION—Subcutaneous apomorphine is a highly effective treatment which can substantially improve the symptomatology in patients with advanced stage Parkinson's disease over a prolonged period of time.



Full Text

The Full Text of this article is available as a PDF (132.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chase T. N., Engber T. M., Mouradian M. M. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol. 1996;69:497–501. [PubMed] [Google Scholar]
  2. Chaudhuri K. R., Critchley P., Abbott R. J., Pye I. F., Millac P. A. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet. 1988 Nov 26;2(8622):1260–1260. doi: 10.1016/s0140-6736(88)90860-4. [DOI] [PubMed] [Google Scholar]
  3. Colosimo C., Merello M., Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol. 1994 Jun;17(3):243–259. doi: 10.1097/00002826-199406000-00004. [DOI] [PubMed] [Google Scholar]
  4. Corboy D. L., Wagner M. L., Sage J. I. Apomorphine for motor fluctuations and freezing in Parkinson's disease. Ann Pharmacother. 1995 Mar;29(3):282–288. doi: 10.1177/106002809502900310. [DOI] [PubMed] [Google Scholar]
  5. Corsini G. U., Del Zompo M., Gessa G. L., Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet. 1979 May 5;1(8123):954–956. doi: 10.1016/s0140-6736(79)91725-2. [DOI] [PubMed] [Google Scholar]
  6. Deffond D., Durif F., Tournilhac M. Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):101–103. doi: 10.1136/jnnp.56.1.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dewey R. B., Jr, Maraganore D. M., Ahlskog J. E., Matsumoto J. Y. Intranasal apomorphine rescue therapy for parkinsonian "off" periods. Clin Neuropharmacol. 1996 Jun;19(3):193–201. doi: 10.1097/00002826-199619030-00001. [DOI] [PubMed] [Google Scholar]
  8. Durif F., Deffond D., Dordain G., Tournilhac M. Apomorphine and diphasic dyskinesia. Clin Neuropharmacol. 1994 Feb;17(1):99–102. [PubMed] [Google Scholar]
  9. Durif F., Deffond D., Tournilhac M. Efficacy of sublingual apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1105–1105. doi: 10.1136/jnnp.53.12.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Frankel J. P., Lees A. J., Kempster P. A., Stern G. M. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):96–101. doi: 10.1136/jnnp.53.2.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gancher S. T., Nutt J. G., Woodward W. R. Absorption of apomorphine by various routes in parkinsonism. Mov Disord. 1991;6(3):212–216. doi: 10.1002/mds.870060304. [DOI] [PubMed] [Google Scholar]
  12. Gancher S. T., Nutt J. G., Woodward W. R. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord. 1995 Jan;10(1):37–43. doi: 10.1002/mds.870100108. [DOI] [PubMed] [Google Scholar]
  13. Gancher S. T., Woodward W. R., Boucher B., Nutt J. G. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol. 1989 Aug;26(2):232–238. doi: 10.1002/ana.410260209. [DOI] [PubMed] [Google Scholar]
  14. Gancher S. Pharmacokinetics of apomorphine in Parkinson's disease. J Neural Transm Suppl. 1995;45:137–141. [PubMed] [Google Scholar]
  15. Gassen M., Glinka Y., Pinchasi B., Youdim M. B. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol. 1996 Jul 18;308(2):219–225. doi: 10.1016/0014-2999(96)00291-9. [DOI] [PubMed] [Google Scholar]
  16. Gálvez-Jiménez N., Lang A. E. Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone. Can J Neurol Sci. 1996 Aug;23(3):198–203. doi: 10.1017/s0317167100038518. [DOI] [PubMed] [Google Scholar]
  17. Hughes A. J., Bishop S., Kleedorfer B., Turjanski N., Fernandez W., Lees A. J., Stern G. M. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord. 1993 Apr;8(2):165–170. doi: 10.1002/mds.870080208. [DOI] [PubMed] [Google Scholar]
  18. Hughes A. J., Bishop S., Lees A. J., Stern G. M., Webster R., Bovingdon M. Rectal apomorphine in Parkinson's disease. Lancet. 1991 Jan 12;337(8733):118–118. doi: 10.1016/0140-6736(91)90780-s. [DOI] [PubMed] [Google Scholar]
  19. Hughes A. J., Lees A. J., Stern G. M. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet. 1990 Jul 7;336(8706):32–34. doi: 10.1016/0140-6736(90)91531-e. [DOI] [PubMed] [Google Scholar]
  20. Johansson F., Malm J., Nordh E., Hariz M. Usefulness of pallidotomy in advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):125–132. doi: 10.1136/jnnp.62.2.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kapoor R., Turjanski N., Frankel J., Kleedorfer B., Lees A., Stern G., Bovingdon M., Webster R. Intranasal apomorphine: a new treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990 Nov;53(11):1015–1015. doi: 10.1136/jnnp.53.11.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kempster P. A., Frankel J. P., Stern G. M., Lees A. J. Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990 Nov;53(11):1004–1007. doi: 10.1136/jnnp.53.11.1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kempster P. A., Iansek R., Larmour I. Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations. Aust N Z J Med. 1991 Jun;21(3):314–318. doi: 10.1111/j.1445-5994.1991.tb04696.x. [DOI] [PubMed] [Google Scholar]
  24. Kleedorfer B., Turjanski N., Ryan R., Lees A. J., Milroy C., Stern G. M. Intranasal apomorphine in Parkinson's disease. Neurology. 1991 May;41(5):761–762. doi: 10.1212/wnl.41.5.761-a. [DOI] [PubMed] [Google Scholar]
  25. Kreczy-Kleedorfer B., Wagner M., Bösch S., Poewe W. Langzeitergebnisse kontinuierlicher subkutaner Apomorphinpumpentherapie bei Patienten mit fortgeschrittener Parkinson-Krankheit. Nervenarzt. 1993 Apr;64(4):221–225. [PubMed] [Google Scholar]
  26. Langston J. W., Widner H., Goetz C. G., Brooks D., Fahn S., Freeman T., Watts R. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992;7(1):2–13. doi: 10.1002/mds.870070103. [DOI] [PubMed] [Google Scholar]
  27. Lees A. J. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol. 1993;7(3-4):121–128. doi: 10.1111/j.1472-8206.1993.tb00226.x. [DOI] [PubMed] [Google Scholar]
  28. Montastruc J. L., Rascol O., Senard J. M., Houin G., Rascol A. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease? J Neural Transm Suppl. 1995;45:157–161. [PubMed] [Google Scholar]
  29. Muguet D., Broussolle E., Chazot G. Apomorphine in patients with Parkinson's disease. Biomed Pharmacother. 1995;49(4):197–209. doi: 10.1016/0753-3322(96)82620-5. [DOI] [PubMed] [Google Scholar]
  30. Muhiddin K. A., Roche M. T., Pearce V. R. Subcutaneous apomorphine infusion in Parkinson's disease: does it have a role? Postgrad Med J. 1994 May;70(823):344–346. doi: 10.1136/pgmj.70.823.344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Nicolle E., Pollak P., Serre-Debeauvais F., Richard P., Gervason C. L., Broussolle E., Gavend M. Pharmacokinetics of apomorphine in parkinsonian patients. Fundam Clin Pharmacol. 1993;7(5):245–252. doi: 10.1111/j.1472-8206.1993.tb00238.x. [DOI] [PubMed] [Google Scholar]
  32. Nutt J. G., Woodward W. R., Hammerstad J. P., Carter J. H., Anderson J. L. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med. 1984 Feb 23;310(8):483–488. doi: 10.1056/NEJM198402233100802. [DOI] [PubMed] [Google Scholar]
  33. Obeso J. A., Grandas F., Vaamonde J., Rosario Luguin M., Martínez-Lage J. M. Apomorphine infusion for motor fluctuations in Parkinson's disease. Lancet. 1987 Jun 13;1(8546):1376–1377. doi: 10.1016/s0140-6736(87)90679-9. [DOI] [PubMed] [Google Scholar]
  34. Ostergaard L., Werdelin L., Odin P., Lindvall O., Dupont E., Christensen P. B., Boisen E., Jensen N. B., Ingwersen S. H., Schmiegelow M. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995 Jun;58(6):681–687. doi: 10.1136/jnnp.58.6.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Pollak P., Benabid A. L., Limousin P., Gervason C. L., Jeanneau-Nicolle E. External and implanted pumps for apomorphine infusion in parkinsonism. Acta Neurochir Suppl (Wien) 1993;58:48–52. doi: 10.1007/978-3-7091-9297-9_10. [DOI] [PubMed] [Google Scholar]
  36. Pollak P., Champay A. S., Hommel M., Perret J. E., Benabid A. L. Subcutaneous apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989 Apr;52(4):544–544. doi: 10.1136/jnnp.52.4.544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Przedborski S., Levivier M., Raftopoulos C., Naini A. B., Hildebrand J. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov Disord. 1995 Jan;10(1):28–36. doi: 10.1002/mds.870100107. [DOI] [PubMed] [Google Scholar]
  38. Quinn N. Drug treatment of Parkinson's disease. BMJ. 1995 Mar 4;310(6979):575–579. doi: 10.1136/bmj.310.6979.575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ray-Chaudhuri K., Abbott R. J., Millac P. A. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment. J Neurol Neurosurg Psychiatry. 1991 Apr;54(4):372–373. doi: 10.1136/jnnp.54.4.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Rodriguez M., Lera G., Vaamonde J., Luquin M. R., Obeso J. A. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. J Neurol Neurosurg Psychiatry. 1994 May;57(5):562–566. doi: 10.1136/jnnp.57.5.562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. SCHWAB R. S., AMADOR L. V., LETTVIN J. Y. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc. 1951;56:251–253. [PubMed] [Google Scholar]
  42. Steiger M. J., Quinn N. P., Marsden C. D. The clinical use of apomorphine in Parkinson's disease. J Neurol. 1992 Aug;239(7):389–393. doi: 10.1007/BF00812157. [DOI] [PubMed] [Google Scholar]
  43. Stibe C. M., Lees A. J., Kempster P. A., Stern G. M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988 Feb 20;1(8582):403–406. doi: 10.1016/s0140-6736(88)91193-2. [DOI] [PubMed] [Google Scholar]
  44. Stibe C., Lees A., Stern G. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet. 1987 Apr 11;1(8537):871–871. doi: 10.1016/s0140-6736(87)91660-6. [DOI] [PubMed] [Google Scholar]
  45. van Laar T., Jansen E. N., Neef C., Danhof M., Roos R. A. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov Disord. 1995 Jul;10(4):433–439. doi: 10.1002/mds.870100405. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES